Terazosin: Intravenous Safety Evaluation in Rats
| Autor: | F. L. Fort, J. W. Kesterson, K.R. Majors, P. K. Cusick, S. Tekeli, I. A. Heyman |
|---|---|
| Rok vydání: | 1984 |
| Předmět: |
Male
Dose Health Toxicology and Mutagenesis Toxicology Piperazines Body Temperature Eating Terazosin medicine Animals Blepharoptosis Antihypertensive Agents Pharmacology Chemical Health and Safety Dose-Response Relationship Drug business.industry Body Weight Public Health Environmental and Occupational Health Antagonist Splenic congestion Rats Inbred Strains Prazosin General Medicine Hypothermia Rats Liver Anesthesia Cardiorespiratory failure Injections Intravenous Toxicity Female medicine.symptom Hypoactivity business medicine.drug |
| Zdroj: | Drug and Chemical Toxicology. 7:435-449 |
| ISSN: | 1525-6014 0148-0545 |
| DOI: | 10.3109/01480548408994211 |
| Popis: | Terazosin, an alpha-adrenergic antagonist, was administered as a 15 mg/ml solution to rats intravenously at a rate of 2 ml/min. Under these conditions the LD50 was 277 mg/kg for males and 293 mg/kg for females. When administered daily for 1 month at dosages of 0, 10, 40 or 150 mg/kg/day, the no-toxic-effect dosage was 40 mg/kg/day. Evidence of toxicity at 150 mg/kg included hypothermia and deaths. Death resulted from acute, exaggerated pharmacologic effects leading to cardiorespiratory failure. Evidence of sympatholytic activity observed at lower dosages included hypoactivity, blepharoptosis, ptyalism and splenic congestion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|